News & Updates
Showing Cardiology articles
Showing

Do cardiovascular drugs worsen COVID-19 outcomes?
Cardiovascular medications, such as angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blocker (ARBs) and anticoagulants, do not induce poor clinical outcomes in patients with COVID-19 and thus should not be discontinued, suggest the results of a meta-analysis.

VTE prevention in pregnancy: Does heparin dose matter?
In pregnant women with a history of venous thromboembolism (VTE), receipt of low-molecular-weight heparin (LMWH) at either a weight-adjusted intermediate-dose or fixed low-dose during the antepartum and postpartum periods results in similar VTE incidence, according to findings of the Highlow study. However, there was a numerically lower incidence of VTE during the postpartum period with intermediate-dose LMWH.

SGLT2 inhibitors show renal benefits vs GLP-1 RAs in T2D patients in the real world
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are superior to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing renal outcomes among patients with type 2 diabetes (T2D) in Hong Kong, a real-world population-based study by the University of Hong Kong has shown.

Neutrophils release more cytokines in DM, HFpEF patients
In patients with type 2 diabetes mellitus (DM) or heart failure with preserved ejection fraction (HFpEF), neutrophils seem to secrete more cytokines, contributing to low-grade chronic inflammation, a recent study reports.

Myopericarditis risk after COVID-19 vaccine not greater than after other vaccines
The risk of myopericarditis after COVID-19 vaccination is not greater than that following other non–COVID-19 vaccinations, according to a systematic review and meta-analysis conducted by researchers in Singapore.




